159 related articles for article (PubMed ID: 34982278)
1. LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer.
Zhao P; Yun Q; Li A; Li R; Yan Y; Wang Y; Sun H; Damirin A
Med Oncol; 2022 Jan; 39(2):17. PubMed ID: 34982278
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.
Yu S; Murph MM; Lu Y; Liu S; Hall HS; Liu J; Stephens C; Fang X; Mills GB
J Natl Cancer Inst; 2008 Nov; 100(22):1630-42. PubMed ID: 19001604
[TBL] [Abstract][Full Text] [Related]
3. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
Yu X; Zhang Y; Chen H
BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
[TBL] [Abstract][Full Text] [Related]
4. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA
Park J; Jang JH; Oh S; Kim M; Shin C; Jeong M; Heo K; Park JB; Kim SR; Oh YS
Cell Signal; 2018 Apr; 44():138-147. PubMed ID: 29329782
[TBL] [Abstract][Full Text] [Related]
5. LPA
Wang F; Liu S; Pei J; Cai L; Liu N; Liang T; Dong X; Cong X; Chun J; Chen J; Hu S; Chen X
Theranostics; 2020; 10(24):10892-10907. PubMed ID: 33042260
[No Abstract] [Full Text] [Related]
6. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid signaling via LPA
Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
9. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.
Chen H; Wu X; Pan ZK; Huang S
Cancer Res; 2010 Dec; 70(23):9979-90. PubMed ID: 21118970
[TBL] [Abstract][Full Text] [Related]
10. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.
Kim EK; Park JM; Lim S; Choi JW; Kim HS; Seok H; Seo JK; Oh K; Lee DS; Kim KT; Ryu SH; Suh PG
J Biol Chem; 2011 Jul; 286(27):24036-45. PubMed ID: 21602274
[TBL] [Abstract][Full Text] [Related]
11. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
[TBL] [Abstract][Full Text] [Related]
13. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.
David M; Ribeiro J; Descotes F; Serre CM; Barbier M; Murone M; Clézardin P; Peyruchaud O
Int J Oncol; 2012 Apr; 40(4):1133-41. PubMed ID: 22200658
[TBL] [Abstract][Full Text] [Related]
14. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
Tanyi J; Rigó J
Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
16. Roles of endothelial cells in the regulation of cell motility via lysophosphatidic acid receptor-2 (LPA
Minami K; Ueda N; Ishimoto K; Kurisu R; Takamoto M; Ikeda H; Tsujiuchi T
Exp Mol Pathol; 2021 Feb; 118():104596. PubMed ID: 33347862
[TBL] [Abstract][Full Text] [Related]
17. Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer.
Ha JH; Radhakrishnan R; Nadhan R; Gomathinayagam R; Jayaraman M; Yan M; Kashyap S; Fung KM; Xu C; Bhattacharya R; Mukherjee P; Isidoro C; Song YS; Dhanasekaran DN
Cancer Lett; 2024 Jun; 591():216891. PubMed ID: 38642607
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways.
Hurst JH; Hooks SB
Pharmacology; 2009; 83(6):333-47. PubMed ID: 19420982
[TBL] [Abstract][Full Text] [Related]
19. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.
Zuckerman V; Sokolov E; Swet JH; Ahrens WA; Showlater V; Iannitti DA; Mckillop IH
Oncotarget; 2016 Jan; 7(3):2951-67. PubMed ID: 26701886
[TBL] [Abstract][Full Text] [Related]
20. Involvement of LPA signaling via LPA receptor-2 in the promotion of malignant properties in osteosarcoma cells.
Takahashi K; Fukushima K; Tanaka K; Minami K; Ishimoto K; Otagaki S; Fukushima N; Honoki K; Tsujiuchi T
Exp Cell Res; 2018 Aug; 369(2):316-324. PubMed ID: 29859140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
